GSK presents positive data for AREXVY, its respiratory syncytial …
WEB2 days ago · GSK plc (LSE/NYSE: GSK) today announced new data from the AReSVi-006 (Adult Respiratory Syncytial Virus) phase III trial evaluating the efficacy and safety of a single dose of AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) against lower respiratory tract disease (LRTD) caused by respiratory syncytial virus …
GSK Presents Positive Data for AREXVY, Its Respiratory Syncytial …
WEB2 days ago · PHILADELPHIA, October 08, 2024--GSK presents positive data for AREXVY, its respiratory syncytial virus (RSV) vaccine, indicating protection over three RSV seasons
GSK announces positive topline data on co-administration of AREXVY …
WEBGSK plc (LSE/NYSE: GSK) today announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, reactogenicity and safety of …
US FDA approves GSK’s AREXVY, the world’s first respiratory …
WEBMay 3, 2023 · US FDA approves GSK’s AREXVY, the world’s first respiratory syncytial virus (RSV) vaccine for older adults. Ground-breaking approval enables adults aged 60 years and older to be protected from RSV disease for the first time.
FDA Approves First Respiratory Syncytial Virus (RSV) Vaccine
WEBMay 4, 2023 · The FDA has approved Arexvy, the first RSV vaccine approved for use in the U.S. Arexvy is approved for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years of...
US FDA Approves Expanded Age Indication for GSK’s AREXVY
WEBPHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved AREXVY (Respiratory …
New data for Arexvy, GSK’s RSV vaccine, show potential to help …
WEBGSK plc (LSE/NYSE: GSK) today announced positive preliminary results from its phase III trial [NCT05590403] evaluating the immune response and safety of Arexvy (respiratory …
US FDA approves GSK’s Arexvy, the world’s first respiratory …
WEBMay 3, 2023 · Arexvy is a recombinant subunit vaccine with adjuvant that prevents lower respiratory tract disease caused by RSV in adults 60 years and older. The US FDA approval is based on a phase III trial that showed 82.6% efficacy against RSV-LRTD and 94.1% efficacy against severe RSV-LRTD.
About Arexvy (respiratory syncytial virus vaccine, adjuvanted) - GSK
WEBGSK plc (LSE/NYSE: GSK) today announced new data from the AReSVi-006 (Adult Respiratory Syncytial Virus) phase III trial evaluating the efficacy of a single dose of …
GSK’s Widely Used RSV Shot Retains 43% Potency In Third Year, …
WEB21 hours ago · GSK said on Tuesday that its Arexvy respiratory syncytial virus vaccine was 43.3% effective in preventing severe illness in its third season after patients received the shot. That compares with 94.1% effectiveness in preventing severe RSV in the first season and 64.2% a year later, according to data from GSK's Phase 3 clinical trial.